The development and progression of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) remains inadequately understood. There are now more than 200 women worldwide who have been diagnosed with BIA-ALCL.
1 The single most common presentation of BIA-ALCL is an accumulation of fluid (periprosthetic fluid/late seroma) occurring on average 9 to 10 years following implantation.
1 The association of anaplastic lymphoma kinase (ALK)-negative ALCL arising within this fluid and the surrounding capsule has led to the description of a distinct malignancy. BIA-ALCL is CD30+, ALK-, and usually CD4+. Clonal T-cell receptor gene rearrangements have been detected in clinical specimens and cell lines derived from BIA-ALCL.
1,2 High expression of JUNB (a transcription factor for which there is no known abbreviation), suppressor of cytokine signaling 3, and special AT-rich sequencing-binding protein-1 have been reported as potential biomarkers of malignant cells in BIA-ALCL, similar to cutaneous ALCL.
3 In addition, recent studies have revealed a linear relationship between the number of bacteria/biofilm on the implant surface and the amount of T lymphocytic infiltrate on textured implants associated with BIA-ALCL.
4